MRNA vaccine aims to shield transplant patients from EBV threat
NCT ID NCT07674199
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This early-phase trial tests an experimental mRNA vaccine (WGc-0401) designed to prevent diseases caused by the Epstein-Barr virus (EBV) in people who have received a stem cell transplant. Twenty participants will receive three vaccine injections after transplant and be closely monitored for safety and immune response. The goal is to find the best dose and see if the vaccine can reduce EBV-related complications like post-transplant lymphoproliferative disorder.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- EBV mRNA vaccine (WGc-0401 injection)
- What this could lead to
- If successful, this vaccine could help prevent serious EBV-related complications in stem cell transplant recipients, improving survival and quality of life.
- What could go wrong
- This is a very early, small trial (20 participants) focused on safety and dosing. The vaccine may not provide sufficient protection or could cause side effects like graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
14 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥14 years, regardless of gender; * Patients undergoing allogeneic hematopoietic stem cell transplantation; * Voluntary participation in the clinical study and signing of the informed consent form. Exclusion Criteria: * History of vaccine allergy; * Presence of active acute graft-versus-host disease (aGVHD) at screening; * Severe impairment of cardiac, hepatic, or renal function; * Body temperature \>38°C within 72 hours prior to enrollment; * Inability to communicate reliably with the investigator or unlikely to comply with study requirements; * Any other condition deemed by the investigator to make the patient unsuitable for enrollment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Patients after hematopoietic stem cell transplantation are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The General Hospital of Western Theater Command
Chengdu, Sichuan, China